Clinical trials: Affective Disorder
Pain, Postoperative, Depression, Postpartum
Ketamine Tolerated Dose for Postpartum Depression and Pain After Cesarean Delivery (PREPARE 1)
The purpose of this study is to identify a tolerable dose for postpartum ketamine infusion using a maximum tolerated dose (MTD) 3+3 design.
- Trial name
- NCT05907213
- Testing
- Ketamine (Ketalar) Dose Level 1, Ketamine (Ketalar) Dose Level 2, Ketamine (Ketalar) Dose Level 3
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Grace Lim, MD, MS
Depressive Disorder, Major
A Safety Study in Participants With Major Depressive Disorder
The primary objective of this study is to evaluate the long-term safety and tolerability of LY2216684 administered once daily (QD) in the adjunctive treatment with a selective serotonin reuptake inhibitor (SSRI) for up to…
- Trial name
- NCT01155661
- Testing
- LY2216684 (edivoxetine), SSRI
- Where
- 48 sites in United States, Brazil and 5 more
- Volunteers
- 608 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Long-Term Administration Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder
To examine the safety and efficacy of long term administration of aripiprazole as an adjunctive therapy, co-administered with either a selective serotonin reuptake inhibitor (SSRI) or a selective-norepinephrine reuptake inhibitor…
- Trial name
- NCT00882362
- Testing
- OPC-14597 (Aripiprazole)
- Where
- 8 sites in Japan
- Volunteers
- 155 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Antenatal Depression, Major Depressive Disorder
Pilot Study of Personalized Aperiodic Transcranial Alternating Current Stimulation in Antenatal Depression (PandA-tACS)
The purpose of this study is to develop the safety, feasibility, and tolerability of a personalized transcranial alternating current stimulation (tACS) approach in antenatal depression.
- Conditions
- Antenatal Depression, Major Depressive Disorder, Major Depressive Disorder in Pregnancy, Healthy Controls
- Trial name
- PandA-tACS (NCT06979154)
- Testing
- tACS (aperiodic)
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Bipolar Disorder, Alcohol Abuse
Efficacy and Tolerability of Topiramate in Treatment of Bipolar Mania and Alcohol Use in Adolescents and Young Adults
The purpose of this research study is to study the effects (both good and bad) of combining quetiapine and topiramate for treating symptoms of bipolar mania (an illness with periods of elation, excessive excitement, irritability…
- Trial name
- NCT00550394
- Testing
- Quetiapine and Topiramate
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- University of Cincinnati
Major Depressive Disorder
Development of Pregnenolone as a Treatment for Depression
Pregnenolone, an over-the-counter supplement, is a naturally occurring neurosteroid made in the adrenal glands and brain. Preclinical research suggests pregnenolone has antidepressant, cognitive enhancing, and neuroprotective…
- Trial name
- NCT03645096
- Testing
- Pregnenolone 500 mg, Pregnenolone 800 mg
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Texas Southwestern Medical Center
Depressive Disorder, Major
54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide
The purpose of this study is to evaluate the efficacy of intranasal esketamine 84 milligram (mg) compared with intranasal placebo in addition to comprehensive standard of care in reducing the symptoms of Major Depressive Disorder…
- Trial name
- Aspire II (NCT03097133)
- Testing
- Esketamine, Standard of Care
- Where
- 61 sites in United States, Argentina and 10 more
- Volunteers
- 230 people
- Sponsor
- Janssen Research & Development, LLC
Bipolar Depression
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Add-on)
This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe when added to treatment with lithium or Divalproex for the treatment of patients with bipolar I depression.
- Trial name
- NCT00868452
- Testing
- lurasidone + (lithium or divalproex)
- Where
- 71 sites in United States, Czechia and 8 more
- Volunteers
- 348 people
- Sponsor
- Sumitomo Pharma America, Inc.
Depression, Depressive Disorder
Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)
This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of TNX-601 ER monotherapy versus placebo in patients with Major Depressive Disorder (MDD).
- Conditions
- Depression, Depressive Disorder, Depressive Symptoms, Depressive Disorder, Major
- Trial name
- UPLIFT (NCT05686408)
- Testing
- TNX-601 ER
- Where
- 27 sites in United States
- Volunteers
- 132 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Major Depressive Disorder
Efficacy of Adjunctive Exercise for the Behavioral Treatment of Major Depression
Major depressive disorder (MDD) is the leading cause of disability in the developed world and is associated with lost productivity, increased health care utilization, and mortality.
- Trial name
- NCT02176408
- Testing
- Behavioral Activation, Exercise Intervention, Stretching Intervention
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Boston University Charles River Campus
Depressive Disorder, Major
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)
Evaluating the efficacy of vortioxetine 10 mg/day and 20 mg/day versus placebo on depressive symptoms in adolescents (age ≥12 and ≤17 years) with a DSM-5™ (Diagnostic and Statistical Manual of Mental Disorders, 5th edition)…
- Trial name
- NCT02709746
- Testing
- Vortioxetine 10 mg/day, Vortioxetine 20 mg/day, Fluoxetine 20 mg/day
- Where
- 124 sites in United States, Bulgaria and 17 more
- Volunteers
- 784 people
- Sponsor
- H. Lundbeck A/S
Major Depression
A Family-based Primary Care Intervention to Enhance Older Men's Depression Care
Despite the public health importance of clinical depression, more than 50% of depressed adults receive inadequate or no treatment, with even higher rates of under-treatment in men and minorities.
- Trial name
- NCT02143024
- Testing
- Family-based depression intervention, Usual care plus educational materials
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of California, Davis
Premenstrual Dysphoric Disorder
Emotional Processing and Oxytocin Mechanisms in Premenstrual Dysphoric Disorder: A Pilot Study
This research study will look at brain and symptom differences among women with severe premenstrual mood symptoms. One goal of this study is to look at the effects of taking a nasal spray containing oxytocin (a hormone made in…
- Trial name
- NCT02508103
- Testing
- Oxytocin
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Depressive Disorder, Major
A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD)
This is a multi-center, placebo-controlled, randomized, double-blind, parallel-comparison study to confirm the efficacy of 323U66 Sustained Release (SR) orally administered to patients with MDD (Major Depressive Disorder) at…
- Trial name
- NCT01138007
- Testing
- 323U66 SR 150 mg tablet
- Where
- 59 sites in Japan, South Korea
- Volunteers
- 572 people
- Sponsor
- GlaxoSmithKline
Dysthymic Disorder
Escitalopram in the Treatment of Dysthymic Disorder, Double Blind
This is a 12-week double-blind placebo-controlled study of Escitalopram in treatment of dysthymic Disorder (low-grade chronic depression), with a 12 week open-label extension phase.
- Trial name
- NCT00220701
- Testing
- Lexapro (escitalopram)
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- St. Luke's-Roosevelt Hospital Center
Major Depressive Disorder
Venlafaxine ER Long-Term Extension Study for Major Depressive Disorder (MDD)
This is a phase 3, flexible-dose, open-label, multi-center study. The subjects who complete the week 8 visit in the prior double-blind study (B2411263) will be eligible to participate in this study.
- Trial name
- NCT01485887
- Testing
- Venlafaxine ER
- Where
- 25 sites in Japan
- Volunteers
- 50 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Depressive Disorder, Major
A Study of LY2216684 in Participants With Impaired Hepatic Function
The purpose of this study is to evaluate the effect of liver function on how much of the study drug (LY2216684) gets into the blood stream and how long it takes the body to get rid of it.
- Trial name
- NCT01241435
- Testing
- LY2216684
- Where
- 3 sites in United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Investigating the Effectiveness of Telepsychiatry for Treating Major Depression in a Chinese American Nursing Home
The current use of telepsychiatry, or psychiatric care using videoconferencing, is very limited. The present study investigates the use of this method with a depressed Chinese American population in a nursing home.
- Trial name
- NCT00505518
- Testing
- Psychotropic medication (at discretion of psychiatrist), Collaborative psychiatric and primary medical care
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder, Dysthymia
Safety and Efficacy Study of Citalopram and Lithium for the Treatment of Depressive Mood Disorder Symptoms
The investigators hypothesize that patients receiving citalopram in combination with lithium will have a greater reduction in depressive symptoms than patients receiving citalopram in combination with placebo.
- Conditions
- Major Depressive Disorder, Dysthymia, Depression Not Otherwise Specified, Borderline Personality Disorder
- Trial name
- NCT01189812
- Testing
- Lithium Carbonate, Citalopram
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Columbia Northwest Pharmaceuticals
Major Depressive Disorder
A Pharmacokinetic Study on the Effect of LY2216684 on the Active Metabolite of Clopidogrel
The purpose of this study is to measure how much of the study drugs (clopidogrel and LY2216684) reach the blood stream and how long it takes the body to dispose of them and to determine how clopidogrel and LY2216684 might affect…
- Trial name
- NCT01263093
- Testing
- Clopidogrel, LY2216684
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.